New daily pill for kids with ADHD enters key trial
NCT ID NCT07086313
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medication called EB-1020 for children and teenagers with ADHD. It is a once-daily capsule that aims to reduce symptoms like inattention and hyperactivity. The trial involves 315 participants in Japan and China, comparing two doses of the drug against a placebo over 6 weeks. The goal is to see if the drug safely improves ADHD symptoms better than a sugar pill.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
Locations
-
Hokkaido University Hospital
RECRUITINGSapporo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 12-Week play program boost development in At-Risk infants?
- Zapping the brain to sharpen focus: a new hope for adult ADHD?
- Can a phone app curb risky drinking in young adults with ADHD?
- Could a cannabis compound help teens with ADHD?
- Could a plant extract ease ADHD in adults? new trial results are in
- Video games as medicine? new study tests brain training for ADHD kids at home